Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database

Background and objective: The depth of the prostate-specific antigen (PSA) decline after androgen receptor pathway inhibitor (ARPI) treatment combined with androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC) may affect prognosis. The primary objective...

Cijeli opis

Bibliografski detalji

Glavni autori:	Mario Hassi Roman, Kinga Mate, Pedro De Pablos-Rodriguez, Álvaro Zamora Horcajada, Ana Guijarro Cascales, Ángeles Sanchís Bonet, Antoni Vilaseca, Darío Vázquez-Martul Pazos, Estefanía Linares Espinós, Jesús Muñoz Rodríguez, José Manuel de la Morena Gallego, José Ramón Alemán, Juan Gómez Rivas, Luigi Formisano, Maria J. Juan Fita, Marc Costa Planells, Mario Domínguez Esteban, Meritxell Pérez Márquez, Miguel García Sanz, Nagore García Expósito, Natalia Picola, Pol Servian Vives, Raquel Sopeña Sutil, Miguel A. Climent Durán, Miguel Ramírez Backhaus
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2024-12-01
Serija:	European Urology Open Science
Teme:	Prostate cancer Metastatic hormone-sensitive prostate cancer Apalutamide Prostate-specific antigen Response Ultrasensitive assay
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2666168324010875
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!